Navigation Links
Sepsis treatment functions best in difficult cases

According to a new analysis suggests that anti-inflammatory agents work best in cases of sepsis which are life-threatening. Sepsis is a condition of overwhelming infection, in which bacteria invade the blood stream.// It is potentially fatal, because it carries the risk of multiple organ failure. In fact, sepsis claims many lives in the intensive care unit, because patients here are very vulnerable to infection.

Treatment is usually by anti-inflammatory agents, which can damp down the infection. But success of anti-inflammatory agents is variable. Researchers in the US carried out a large retrospective study, covering 20 clinical trials and 35 pre-clinical trials on animals. This revealed that anti-inflammatory agents were most effective when the patient was thought to have the highest risk of death from sepsis. If the risk of death was low, the patient could actually be harmed by anti-inflammatory agents. The researchers then confirmed their findings with tests involving 1,125 rats, exposed to varying doses of anti-inflammatory agents.


'"/>




Page: 1

Related medicine news :

1. Sepsis Death Reported With Mifepristone – FDA Issues Warnin
2. Researchers identify the early makers of Neonatal Sepsis
3. Sepsis risk increased due to the absence of one key enzyme
4. Drexel Research in Cytokines Could Treat Sepsis
5. Thyroid hormone treatment hastens recovery after cardiac surgery
6. Feeding channel created by malaria parasite - a new target for malaria treatments
7. Now umbilical cord helps in stroke treatment.
8. Now AIDS treatment comes dirt-cheap
9. Breast cancer treatment to be determined by gene test
10. Hemopurifier may revolutionise AIDS treatment
11. New drug helps boost cancer treatment
Post Your Comments:
Breaking Medicine Technology:Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 2Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 3Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 4Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 5Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 6Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 7Reportlinker Adds Radiation Therapy Equipment - A Global Market Review 8Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 2Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities 3Global Announces Contract To Acquire New Business 2Wound Management Technologies Inc Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies Inc 12648 1Wound Management Technologies Inc Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies Inc 12648 2Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 1Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 2Carbon Design Innovations Inc Introduces Carbon Nanotube Probe Technology for Atomic Force Microscopy CNT Probes Deliver New Level of AFM Imaging P 12645 3Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 1Finances Trigger American Reluctance to Spend More on Healthier Foods 49018 2
Other Medicine Technology:Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 2Biomira Selects PX-866 as Clinical Development Candidate and,Presents Promising Preclinical Data at AACR 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9